Profiles: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 10: | Line 10: | ||
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ||
Link to QIBA Public Comment Form: http://tinyurl.com/y8dy2pc2 | |||
*[[Media:QIBA_fMRI_Profile_1_PC.pdf| QIBA fMRI Profile 2017-06-19]] ''Public Comment to open on June 19, 2017'' | *[[Media:QIBA_fMRI_Profile_1_PC.pdf| QIBA fMRI Profile 2017-06-19]] ''Public Comment to open on June 19, 2017'' | ||
Revision as of 20:56, 15 June 2017
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Stage 3: Technically Confirmed Profiles
Stage 2: Consensus Profiles
Stage 1: Public Comment Profiles
Link to QIBA Public Comment Form: http://tinyurl.com/y8dy2pc2
- QIBA fMRI Profile 2017-06-19 Public Comment to open on June 19, 2017
- QIBA PET Amyloid Profile 2017-06-15 (Public Comment Form: http://tinyurl.com/y8dy2pc2) Public Comment is open for 90 days - until September 15, 2017
- DWI Profile 2017-04-27 (Public Comment Form: https://goo.gl/fkL6rB)
- DCE-MRI Quantification 2011-12-13 (Public Comment ended Feb 2012)
- Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)